Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/22/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Mazen Jamal

Wrong Dr. Mazen Jamal?

Clinical Professor of Medicine

Phone: (949) ***-****  HQ Phone
University of California , Irvine
801 E. Peltason Dr.
Irvine , California 92617
United States

Company Description: About the University of California, Irvine: Founded in 1965, UCI is a top-ranked university dedicated to research, scholarship and community service. Led by...   more
Background

Employment History

Education

  • M.D.
  • M.P.H.
14 Total References
Web References
Medical Tourism Experts - Gerson Lehrman Group
www.glgresearch.com, 22 Nov 2013 [cached]
Mazen Jamal
Chief of Endoscopy UNITED STATES DEPT OF VETERANS AFFAIRS SM is our premium Member ProgramSM. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG. ">
Mazen Jamal, MD, MPH, is Chief of Gastrointestinal Endoscopy and Outpatient Services at the Long Beach VA Medical Center. Dr. Jamal is also Clinical Professor of Medicine at the University of California, Irvine and consults through his own company, MMJ...
Mazen Jamal, who works as a ...
www.gazettes.com, 10 Sept 2008 [cached]
Mazen Jamal, who works as a gastroenterologist at the VA Long Beach Healthcare System, has partnered with a therapeutic company to develop a stem cell-based treatment for patients with moderate to severe Crohn's disease.Medication would use cells derived from human bone marrow and would alleviate symptoms caused by the condition, such as stomach ulcers and intestinal inflammation.
"Based on trial results, this looks to be one of the most promising treatments for these types of patients," said Jamal, who also teaches in the field at the University of California, Irvine."The majority of patients have (gone) into remission and have improved significantly."
Enrollment for the third phase of the clinical trial is taking place and will put patients on an intravenous drug therapy known as Prochymal.The treatment uses what are called mesenchymal stem cells that move to damaged areas of the body and catalyze tissue repair.
"It's an infusion of stem cells taken from donors," Jamal explained."…If a patient develops ulcers or inflammation, it leads to the secretion of anti-inflammatory chemicals that fight these and lead to healing."
If all goes as planned, Jamal said, Prochymal could be on the market in an estimated two-and-a-half to three years, after receiving approval from the U.S. Food and Drug Administration.But before that can happen, Jamal will work as a principal investigator, encouraging interested patients to participate in the trial.
"When it started, the FDA put it on the fast track, because they believe it's a needed medication and that it showed substantial efficacy from the trial," Jamal said.
If the medication receives approval, it would be administered in hospitals and clinics, not by patients.
Jamal has worked for the VA for seven years and said he was contacted by Osiris Therapeutics to help with the study.Since 1992, the company has sought to develop and market treatments for inflammatory, orthopedic and cardiovascular issues using adult bone marrow (rather than that of fetuses, embryos or animals).
"I'm recruiting patients, examining them and making sure they are a good fit for the study," Jamal said.
"We believe that these data demonstrate ...
investor.sucampo.com, 21 May 2012 [cached]
"We believe that these data demonstrate that lubiprostone may represent an important new treatment option for patients suffering from this condition," said M. Mazen Jamal, M.D., M.P.H., a lead investigator in the trial and Chief of Endoscopy, Long Beach Veterans Affairs' Medical Center, Long Beach, California, Professor, Department of Medicine, University of California College of Medicine at Irvine. Dr. Jamal gave the presentation, entitled " Lubiprostone improves treatment response in opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a Phase 3, randomized, double-blind, placebo-controlled clinical trial ."
Editorial Board of Journal of Gastrointestinal Cancer: Targets and Therapy
www.dovepress.com, 14 July 2011 [cached]
M. Mazen Jamal, Professor of Medicine, University of California at Irvine, CA; Chief of PC & SC Health Care Group, Long Beach VA Medical Center Chief of Endoscopy, Long Beach VA Medical Center; Clinical Research Investigator, Long Beach Veteran Medical Center, CA, USA
News Release
investor.sucampo.com, 7 Jan 2011 [cached]
M. Mazen Jamal, M.D., M.P.H., Chief of Endoscopy, Long Beach Veterans Affairs' Medical Center, Long Beach, California, and Professor, Department of Medicine, University of California College of Medicine at Irvine, and an investigator in the trial, said, "Opioid-induced bowel dysfunction is a common, painful and debilitating side effect of opioid-based pain therapy.
Other People with the name "Jamal":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304